Aficamten secondary endpoints and safety in obstructive HCM
Aficamten significantly improved five of six secondary endpoints compared with metoprolol, per the company. Patients receiving aficamten had greater improvements in New York Heart Association (NYHA) functional class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), post-Valsalva LVOT gradient, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and left atrial volume index (LAVI). Left ventricular mass index did not differ significantly between groups.1,2
In an echocardiographic analysis of MAPLE-HCM, aficamten reduced the Valsalva LVOT gradient by 35 mm Hg (95% CI, −44 to −26; P <.001) and LAVI by 7.0 mL/m2 (95% CI, −9.1 to −4.8; P <.001) relative to metoprolol. Left ventricular ejection fraction (LVEF) declined by 4% (95% CI, −5% to −3%; P <.001) with aficamten vs metoprolol, with no significant between-group difference in resting cardiac output.3
Overall adverse event rates were similar between arms. Hypertension was the most common adverse reaction occurring more often with aficamten (15% vs 3% with metoprolol), while dizziness was the most frequent excess event in the metoprolol arm. In SEQUOIA-HCM, hypertension occurred in 8% of aficamten-treated patients vs 2% of those receiving placebo.1
Aficamten boxed warning, REMS, and drug interactions
Aficamten carries a boxed warning for heart failure due to systolic dysfunction, and echocardiographic LVEF assessment is required before and during treatment. Initiation is not recommended at an LVEF below 55%; the dose should be reduced at an LVEF of 40% to below 50% and interrupted below 40% or with heart failure symptoms or worsening clinical status. The drug is available only through the Myqorzo REMS program, which requires certification of prescribers and pharmacies and enrollment of patients.1
Concomitant rifampin is contraindicated. Aficamten is metabolized primarily by CYP2C9, with lesser contributions from CYP3A, CYP2D6, and CYP2C19. LVEF should be reassessed two to eight weeks after starting or stopping interacting agents, with dose adjustment as needed.1
“For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition,” Robert Blum, president and chief executive officer of Cytokinetics, said in a statement. “Myqorzo is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its US label, providing cardiologists and patients important information to inform treatment decisions.”1
Cytokinetics plans to submit an sNDA in the fourth quarter of 2026 for aficamten in nonobstructive HCM based on the phase 3 ACACIA-HCM trial. The pediatric CEDAR-HCM study and the FOREST-HCM open-label extension are ongoing, and aficamten is also approved for oHCM in China, the European Union, the United Kingdom, and Canada.1